Promethera Biosciences successfully enrolls twenty patients in its multicentric Phase I/II trial

Promethera Biosciences has conducted the trial in Belgium, France, United Kingdom, Italy and Israel, successfully treating twenty patients affected by very rare liver-based metabolic diseases

Mont-Saint-Guibert (Belgium) - November 12, 2013 – Promethera Biosciences, a Belgian biotechnology company developing Promethera® HepaStem, a cell-based therapy for the treatment of liver-based metabolic diseases including Crigler-Najjar Syndrome and Urea Cycle Disorders, announces today the completion of patient enrolment for its first clinical trial. 

Promethera Biosciences is conducting a first-in-man trial with HepaStem in paediatric patients suffering from orphan diseases. This trial is a prospective, open label, multicenter Phase I/II clinical study involving Urea Cycle Disorders (UCD) and Crigler-Najjar (CN) syndrome paediatric patients.

Sign Up